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Prevalence of Cirrhosis in Hepatitis C Patients in
the Chronic Hepatitis Cohort Study (CHeCS):
A Retrospective and Prospective Observational Study
Stuart C. Gordon, MD1, Lois E. Lamerato2, Loralee B. Rupp3, Scott D. Holmberg4, Anne C. Moorman4, Philip R. Spradling4,
Eyasu Teshale4, Fujie Xu4, Joseph A. Boscarino5, Vinutha Vijayadeva6, Mark A. Schmidt7, Nancy Oja-Tebbe2 and Mei Lu2
for the CHeCS investigators8
OBJECTIVES:

The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States
remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC)
using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker.

METHODS:

Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during
2006–2010 were included. Cirrhosis was identiﬁed through liver biopsy reports, diagnosis/procedure
codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores ≥5.88. Demographic
and clinical characteristics associated with cirrhosis were identiﬁed through multivariable logistic
modeling.

RESULTS:

Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identiﬁed
cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for
cirrhosis and hepatic decompensation identiﬁed cirrhosis in 2,194 (22%), 557 (6%), and 482
(5%) patients, respectively. Among 661 patients with biopsy-conﬁrmed cirrhosis, only 356 (54%)
had an International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV
coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently
associated with higher odds of cirrhosis (all, P<0.05). Conversely, private health insurance coverage,
black race, and HCV genotype 2 were associated with lower odds of cirrhosis.

CONCLUSIONS: A high proportion of patients with biopsy-conﬁrmed cirrhosis are not assigned ICD-9 codes for

cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of
cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of
cirrhosis than is revealed by biopsy alone. These ﬁndings suggest that cirrhosis in CHC patients may
be signiﬁcantly underdocumented and underdiagnosed.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/ajg

Am J Gastroenterol 2015; 110:1169–1177; doi:10.1038/ajg.2015.203; published online 28 July 2015

INTRODUCTION
The health care and economic burden of chronic hepatitis C
virus (HCV) infection in the United States relates primarily to
liver disease severity. Recent estimates suggest that 1% of the

noninstitutionalized civilian population in the United States
is chronically HCV infected, corresponding to ∼ 2.7 million
individuals (1). Progression of chronic hepatitis C (CHC) to
cirrhosis occurs over a period of several years (2). The identification
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of patients with cirrhosis may have significant implications pertaining to the management of CHC and health resource utilization (3).
A recent multicohort natural history model of CHC projected
an increase in the proportion of CHC patients with cirrhosis
from 25% in 2010 to 45% in 2030 (4). A subsequent retrospective
cohort study of a national sample of veterans in the United States
reported an increase in the prevalence of HCV-related cirrhosis
from 9% in 1996 to 18.5% in 2006 and an increase in the prevalence of decompensated cirrhosis from 5% to 11% over the same
period (5). Both studies postulated that the aging of the HCVinfected population and duration of HCV infection accounts for
the increase in the prevalence of cirrhosis; others have shown
that this progression to cirrhosis is significantly associated with
Hispanic ethnicity, socioeconomic status, and metabolic factors
(e.g., hepatic steatosis, obesity, insulin resistance, and diabetes)
(6–14).
Although these published estimates of cirrhosis prevalence
highlight the significant burden of cirrhosis associated with
chronic HCV infection, they may nevertheless underestimate the
true prevalence of cirrhosis. This notion is supported by our recent
observation that estimated that at least two-thirds of all HCVinfected individuals who died in 2010 were likely to have had
unrecognized premortem indications of chronic liver disease (15).
Previous estimates of the prevalence of cirrhosis have included
patients whose cirrhosis was confirmed by liver biopsy or defined
based on the presence of International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) codes for cirrhosis or hepatic decompensation in patient records (5,16,17).
These estimates may have failed to capture a substantial proportion of patients with cirrhosis because liver biopsy is not routinely
performed in clinical practice. Moreover, preferential diagnostic
coding for the underlying HCV infection over the code for cirrhosis may result in erroneous estimates.
The Fibrosis-4 (FIB-4), a simple noninvasive index based on
readily available demographic and laboratory parameters, has
been previously validated as being able to accurately predict
advanced fibrosis in HCV-infected patients with and without HIV
coinfection (18–20). We have previously shown the FIB-4 index to
be superior to other serum marker indices of liver fibrosis (e.g., the
aspartate aminotransferase-to-platelet ratio index (APRI) and the
aspartate aminotransferase-to-alanine aminotransferase ratio) in
its ability to differentiate between mild-to-moderate and advanced
fibrosis for CHC patients in the Chronic Hepatitis Cohort Study
(CHeCS) cohort, a large, geographically and racially diverse cohort
receiving routine care at four large US health-care systems (21,22).
A subsequent study in the same cohort validated the FIB-4 index
for both CHC and chronic hepatitis B and determined optimal
cutoff values for differentiating between F0–F2 (no to moderate
fibrosis), F3 (advanced fibrosis), and F4 (cirrhosis) (23). In the
present study, we sought to estimate the prevalence of cirrhosis
among CHC patients in the CHeCS cohort based on an expanded
set of parameters that included FIB-4 as well as liver biopsy results
and the presence of diagnosis or procedure codes for cirrhosis and
various manifestations of hepatic decompensation.
The American Journal of GASTROENTEROLOGY

METHODS
Study population

The CHeCS cohort—a dynamic, prospective, longitudinal, observational, multicenter cohort—and the process used for cohort
selection have been previously described (22). Adults ≥18 years
of age who met CHeCS electronic identification criteria, whose
CHC infection was confirmed through chart abstraction, and
who received any type of health service between 1 January 2006
and 31 December 2010 at any of the four health systems participating in the CHeCS (Geisinger Health System, Danville, PA;
Henry Ford Health System, Detroit, MI (coordinating center);
Kaiser Permanente Northwest, Portland, OR; and Kaiser Permanente, Honolulu, HI) were included in this study. Patients were
excluded if they were coinfected with the hepatitis B virus, if they
had achieved a sustained viral response to therapy, or if they were
liver transplant recipients.
The CHeCS study protocol was approved at each participating
site between October 2009 and February 2010 by an institutional
review board approved by the Federal Office for Human Research
Protections.
Data collection and analysis

Data pertaining to routine care through the end of 2010 were collected from the electronic health record and supplemented with
individual chart review; these included patient demographics,
medical encounters, laboratory results, diagnoses, and procedures
including liver biopsy results (22). Data regarding the source of
infection were collected through a patient survey, with patients
being permitted to select more than one likely source of infection.
Self-reported data from the same survey were used to determine
the date of infection. Data on household income were estimated
from US census data based on geocoded addresses. Data on antiviral treatment were collected by chart abstraction and included
any available documentation of treatment received at outside
facilities. Data on HCV genotypes were collected from laboratory
records. History of alcohol abuse was determined on the basis of
presence of an ICD-9-CM diagnosis code related to past or present alcohol abuse (291.0–291.9, 303.00–303.93, 305.00–305.03,
or 980.0) in the patients’ medical records. Coinfection with HIV
was determined by the presence of HIV antibodies or a detected
HIV RNA level on quantitative or qualitative testing. Diabetes comorbidity was defined on the basis of the Charlson/Deyo
comorbidity subscore for diabetes, defined as the presence of an
ICD-9-CM diagnosis score for diabetes (250.xx) in the medical
record (24).
Cirrhosis was identified from four sources: (i) liver biopsy reports
(Metavir stage 4 or, if cirrhosis had not been staged, the narrative
diagnosis by a pathologist); (ii) presence of at least one ICD-9-CM
diagnosis code for cirrhosis (571.2 and 571.5); (iii) presence of
at least one ICD-9-CM diagnosis or procedure code or Current
Procedural Terminology (CPT) code associated with a manifestation of hepatic decompensation (Table 1); and (iv) FIB-4
index score. In addition, APRI was used in a sensitivity analysis.
The FIB-4 and APRI indices were calculated as previously described
(18,23,25). For FIB-4, a cutoff value of ≥5.88 that has been previVOLUME 110 | AUGUST 2015 www.amjgastro.com
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Condition

ICD-9-CM and CPT diagnosis and
procedure codes

Liver cancer

155.0, 155.1, 155.2

Liver failure with hepatorenal
syndrome

572.4

Hepatic encephalopathy

572.2

Portal hypertension/portal decompression procedures

572.3
37140, 37160, 37180, 37181,
37182, 37183

Esophageal varices complications
and procedures

456.0, 456.20
43204, 43205, 43243, 43244,
43400, 43401
42.91, 44.91, 96.06

Other GI hemorrhage (selected)

530.7, 530.82, 578.0, 578.1, 578.9

Ascites/paracentesis procedures

789.5, 789.59
49080, 49081
54.91

Other sequelae of chronic liver
disease

572.8

CPT, Current Procedural Terminology; GI, gastrointestinal; ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation.

Table 2. Population characteristics
Characteristic

N=9,783

a

Age (mean, s.d.)

55.0 (10.9)

Age categorya
≤40 years

807 (8%)

>40 to <50 years

1,464 (15%)

>50 to <60 years

4,513 (46%)

≥60 years

2,999 (31%)

Male sex

5,752 (59%)

Race
Asian

311 (3%)

White

5,963 (61%)

Black

2,267 (23%)

Paciﬁc Islander/Hawaiian

190 (2%)

Native American

177 (2%)

Unknown

875 (9%)

Hispanic ethnicity

366 (4%)
b

Median annual household income
<$15,000

ously validated as being predictive of cirrhosis in this cohort (23)
was used, whereas cutoff values of >1.0, >1.5, and >2.0 were used
for the APRI index. The most recent values for aminotransferase
levels and platelet counts that had been collected within 7 days of
each other were used. Aminotransferase levels and platelet counts
taken during antiviral therapy were excluded as therapy can influence these parameters. A second sensitivity analysis that excluded
laboratory values collected while patients were hospitalized was
performed in order to eliminate the potential influence of spurious
platelet and/or aminotransferase derangements during hospitalization.

253 (3%)

≥$15,000 to <$30,000

1,877 (19%)

≥$30,000 to <$50,000

4,424 (45%)

≥$50,000 to <$75,000

2,147 (22%)

≥$75,000

548 (6%)

Missing

534 (6%)

Insurance statusb
Medicaid

1,256 (13%)

Medicare

2,281 (23%)

Private

5,623 (57%)

None

289 (3%)

Unknown

334 (3%)

Any HCV antiviral therapy

Statistical methods

Logistic regression—univariate, followed by multivariable modeling—was used to compare the demographic and clinical characteristics of patients with and without an indication of cirrhosis
(by any of the four methods). Variables with P value of <0.05 were
retained in the final multivariable model.

3,586 (37%)

HCV genotype
1

4,687 (48%)

2

830 (8%)

3

613 (6%)

Other

117 (1%)

Unknown

RESULTS
Population characteristics

Table 2 shows the demographic characteristics of the study
population (n=9,783). The mean age of the patients was 55±10.9
years at the time of most recent follow-up. More than one-half of
them were white males and a majority (94%) were insured. Of all
patients, 43% had at least one liver biopsy report during followup, 17% of whom had a recent biopsy <2 years old. The median
follow-up time was 6.4 years.
© 2015 by the American College of Gastroenterology

3,536 (36%)

History of alcohol abuse

2,262 (23%)

HIV coinfection

319 (3%)

Diabetes (Charlson/Deyo comorbidity subscore)

967 (10%)

HCV, hepatitis C virus.
a
At the time of most recent follow-up through 31 December 2010.
b
At the time of enrollment into Chronic Hepatitis Cohort Study (CHeCS).
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Table 3. Proportion of patients with cirrhosis indicated vs. not
indicated
N (%); n=9,783
Cirrhosis not indicated

6,995 (71.5)

Cirrhosis indicated by FIB-4 scores, liver biopsy,
or diagnostic/procedure codes for cirrhosis or
manifestations of hepatic decompensation

2,788 (28.5)

By FIB-4 ≥5.88

2,194 (22.4)

By liver biopsy

661 (6.8)

By diagnostic/procedure codes (for cirrhosis or
manifestations of hepatic decompensation)

751 (7.7)

By ICD-9-CM diagnostic codes for cirrhosis

557 (5.7)

By ICD-9 diagnostic codes/CPT codes for
manifestations of hepatic decompensation

482 (4.9)

By APRI >1.0a

1,825 (18.7)

By APRI >1.5a

1,488 (15.2)

a

1,231 (12.6)

By APRI >2.0

APRI, aspartate aminotransferase-to-platelet ratio index; CPT, Current Procedural Terminology; FIB-4, Fibrosis-4; ICD-9-CM, International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation.
a
APRI scores served as additional criteria for determination of cirrhosis in
sensitivity analyses.

the remaining 431 patients (55%). Discordance between cirrhosis
indicated by FIB-4 scores and by biopsy was seen in only 431 of the
2,194 patients (19.6%).
We explored the possibility that this discordance may have been
due to the performance of the biopsy significantly earlier than the
FIB-4 score calculation. The discordance could indicate that the
FIB-4 score represents a true progression to cirrhosis during the
time interval between the two tests. We therefore analyzed differences in the timing of the FIB-4 relative to the timing of the
biopsy in the 788 patients who had cirrhosis as indicated by FIB-4
scores and had a biopsy performed, comparing patients showing
concordance with those showing discordance with regard to the
two measures. We compared the elapsed time of the earliest indication of cirrhosis by FIB-4 scores from the time of biopsy. The
median elapsed time from biopsy to FIB-4 was 37.9 months among
the patients with concordance and 46.8 months in patients with
discordance (including negative times in cases where the biopsy
was performed after FIB-4 scores were calculated). Although the
differences between the two groups was not significant based on a
nonparametric Wilcoxon test, it is possible that a cirrhotic FIB-4
score measured almost 4 years after a noncirrhotic biopsy could
indeed represent progression to cirrhosis.
Sensitivity analysis

Indication of cirrhosis

Of the 9,783 patients in the cohort, cirrhosis was indicated by at
least one method in 2,788 patients (28.5%) (Table 3). Of these,
2,194 (22.4%) had FIB-4 scores ≥5.88, 661 patients (6.8%) were
diagnosed with cirrhosis by liver biopsy, and 751 patients (7.7%)
had diagnostic/procedure codes for cirrhosis or manifestations
of hepatic decompensation (of whom 557 patients (5.7%) and
482 patients (4.9%) had diagnostic or procedure codes for cirrhosis and hepatic decompensation, respectively). Cirrhosis was
indicated exclusively by FIB-4 scores in 1,727 patients (17.6%)
and was indicated by all methods (FIB-4 score, liver biopsy, and
presence of a diagnostic/procedure code for cirrhosis or hepatic
decompensation) in only 221 patients (2.3%). Notably, of the
661 patients with cirrhosis identified by biopsy, only 356 (53.9%)
also had ICD-9-CM/CPT codes for cirrhosis or manifestations of
hepatic decompensation (Supplementary Table S1 online).
Among the 2,194 patients whose FIB-4 scores were ≥5.88, only
357 patients (16%) had been diagnosed with cirrhosis by liver
biopsy results, whereas 326 patients (15%) had ICD-9-CM/CPT
codes for cirrhosis or manifestations of hepatic decompensation.
When APRI scores >1.0, >1.5, and >2.0 were also taken into consideration, cirrhosis was indicated in 1,659 (75.6%), 1,402 (63.8%),
and 1,186 (54.0%) patients, respectively; cirrhosis remained
indicated solely by FIB-4 scores in only 433 patients (19.7%)
(Supplementary Table S2). Of the 2,194 patients with cirrhosis indicated by FIB-4 scores ≥5.88, only 788 patients (36%) had
a biopsy performed at any time (Supplementary Table S3). Of
these 788 patients, 357 patients (45%) had a biopsy indicating
cirrhosis (concordance), whereas cirrhosis was not indicated in
The American Journal of GASTROENTEROLOGY

In the second sensitivity analysis, exclusion of FIB-4 scores from
lab values collected during hospitalizations resulted in a reduction in the number of patients with FIB-4 scores ≥5.88 from 2,185
(22%) to 1,757 (18%). There was a corresponding decrease in the
overall number of patients with an indication of cirrhosis by at
least one of the methods from 2,788 (28%) to 2,422 (25%).
Demographic and clinical characteristics of patients with
cirrhosis

Univariate analysis of the demographic and clinical characteristics of patients with an indication of cirrhosis (by any of the
four methods), compared with those without indication of cirrhosis, revealed that age, gender, race/ethnicity, median annual
household income, insurance status, receipt of any HCV antiviral
therapy, HCV genotype, history of alcohol abuse, HIV coinfection, and diabetes (as assessed by the Charlson/Deyo comorbidity
subscore) were significantly associated with prevalence of cirrhosis in this cohort (Table 4). Multivariable logistic modeling for
characteristics associated with cirrhosis revealed that older age,
male gender, Asian race (compared with White race), Hispanic
ethnicity, lack of insurance coverage or coverage by Medicare or
Medicaid (compared with private insurance), history of receipt of
antiviral therapy, infection by HCV genotype 3 (compared with
infection by genotype 1), history of alcohol abuse, HIV coinfection, and diabetes were associated with being cirrhotic (Table 5).
Conversely, Black race and infection with HCV genotype 2 were
associated with lower odds of being cirrhotic.
Source of infection

We collected data regarding source of infection among a subgroup of 4,218 patients who completed a survey to examine
VOLUME 110 | AUGUST 2015 www.amjgastro.com

Table 4. Univariate logistic comparisons of demographic and clinical
characteristics among patients with an indication of cirrhosis (by
any method) and those without an indication of cirrhosis
Characteristic

Age (mean, s.d.)

Indication
of cirrhosis,
n=2,788

P valuea

53.6 (11.3)

58.5 (8.9)

<0.001

771 (11%)

36 (1%)

No indication
of cirrhosis,
n=6,995

Age category
≤40 years

<0.001

>40 to <50 years

1,193 (17%)

271 (10%)

>50 to <60 years

3,103 (44%)

1,410 (51%)

≥60 years

1,928 (28%)

1,071 (38%)

3,950 (56%)

1,802 (65%)

Asian

193 (3%)

118 (4%)

White

4,416 (63%)

1,547 (55%)

Black

1,485 (21%)

782 (28%)

Paciﬁc Islander/Hawaiian

121 (2%)

69 (2%)

Native American

129 (2%)

48 (2%)

Unknown

651 (9%)

224 (8%)

237 (3%)

129 (5%)

Male sex
Race

Hispanic ethnicity

<$15,000

172 (2%)
1,302 (19%)

575 (21%)

3,146 (45%)

1,278 (46%)

≥$50,000 to <$75,000

1,556 (22%)

591 (21%)

≥$75,000

399 (6%)

149 (5%)

Missing

420 (6%)

114 (4%)

Insurance status

<0.001

Medicaid

887 (13%)

369 (13%)

Medicare

1,379 (20%)

902 (32%)

Private

4,307 (62%)

1,316 (47%)

183 (3%)

106 (4%)

Unknown

239 (3%)

95 (3%)

2,429 (35%)

1,157 (41%)

1

3,229 (46%)

1,458 (52%)

2

636 (9%)

194 (7%)

3

415 (6%)

198 (7%)

HCV genotype

Other
Unknown
History of alcohol abuse

<0.001
<0.001

85 (1%)

32 (1%)

2,630 (38%)

906 (32%)

1,349 (19%)

913 (33%)

<0.001

HIV coinfection

182 (3%)

137 (5%)

<0.001

Diabetes (Charlson/Deyo
comorbidity subscore)

603 (9%)

364 (13%)

<0.001

HCV, hepatitis C virus.
a
P values for categorical variables are based on the chi-square test, while the
P value for the continuous variable (age) is based on the t-test (unequal variance).

© 2015 by the American College of Gastroenterology

Data on the duration of infection were available for a subgroup
of patients who completed a survey and were able to estimate
when they became infected (n=2,389). Of these, 365 patients
were indicated as having cirrhosis by FIB-4 ≥5.88, whereas
2,024 patients were determined not to have cirrhosis by FIB-4.
To improve our confidence in FIB-4 as a predictor of cirrhosis, we used logistic regression analysis to examine whether, as
we hypothesized, a longer duration of infection was associated
with FIB-4-cirrhosis. We found that the odds of cirrhosis as
indicated by FIB-4 increased with duration of infection (odds
ratio=1.09 for each 5-year duration of infection; 95% Wald confidence interval 1.04–1.14, P<0.0001).

<0.001

81 (3%)

≥$30,000 to <$50,000

Any HCV antiviral therapy

<0.001

<0.001

≥$15,000 to <$30,000

None

Duration of infection

<0.001

Median annual
household income

whether mode of infection was associated with development
of cirrhosis (indicated by FIB-4 ≥5.88, biopsy, or diagnosis
codes). In univariate analysis, we found that contracting hepatitis C through occupational exposure, blood transfusion, or a
medical procedure was associated with higher rates of cirrhosis, whereas exposure by injection drug use or sex with males
was associated with lower rates of cirrhosis (Supplementary
Table S4).

DISCUSSION
This study revealed that the use of parameters in addition
to liver biopsy—including a previously validated serum
biomarker that serves as a surrogate for more advanced
fibrosis—facilitates the identification of previously unrecognized cirrhotic CHC patients. Use of all four parameters
(liver biopsy, FIB-4 scores, and diagnostic/procedural codes
for cirrhosis and manifestations of hepatic decompensation)
suggests a fourfold higher prevalence of cirrhosis than is
indicated by biopsy alone. The estimated prevalence of
cirrhosis of 25–28% in the CHC population at four health
systems in the United States is in agreement with the
previously modeled projection of 25% prevalence of cirrhosis in 2010 (4). These results imply that a quarter of all CHC
patients under medical care may be cirrhotic, but that most
have never been formally assigned this diagnosis and may be
unaware of their cirrhosis. Moreover, only half of all patients
with biopsy-confirmed cirrhosis are assigned an ICD-9 code
for cirrhosis. Consequently, ICD-9 codes may not be reliable
as the sole indicator of the prevalence of cirrhosis in cohort
studies.
The present analysis corroborates earlier reports indicating
that age, alcohol abuse, male gender, coinfection with HIV, and
diabetes are associated with a significant increase in the risk of
progression to cirrhosis (14,26–29). Our observation that Hispanic ethnicity increases the risk of progression to cirrhosis is
in agreement with findings of other studies that have evaluated
the role of ethnicity in the progression of hepatitis C infections
to cirrhosis (6–9); similarly, our finding that African Americans are at lower risk of cirrhosis compared with Caucasians is
also in agreement with findings of other studies (8,27,29,30).
The American Journal of GASTROENTEROLOGY
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Table 5. Multivariable logistic model of characteristics associated
with cirrhosis (indicated by any method)
Characteristic

Adjusted odds ratio
(95% CI)

Age category
<40 years

<0.001
1 (reference)

>40–50 years

5.04 (3.49–7.28)*

>50–60 years

10.65 (7.49–15.15)*

≥60 years

12.63 (8.81–18.11)*

Sex
Male
Female

0.003
1 (reference)
0.86 (0.78–0.95)*

Race
White

<0.001
1 (reference)

Asian

1.59 (1.22–2.06)*

Black

0.81 (0.70–0.92)*

Paciﬁc Islander/Hawaiian

1.28 (0.90–1.80)

Native American

0.97 (0.68–1.39)

Hispanic ethnicity
Not Hispanic
Hispanic

<0.001
1 (reference)
1.36 (1.05–1.75)*

Insurance
Private

P value

<0.001
1 (reference)

Medicaid

1.80 (1.54–2.11)*

Medicare

1.73 (1.54–1.94)*

No insurance

2.14 (1.62–2.82)*

Any HCV antiviral therapy

<0.001

No

1 (reference)

Yes

1.43 (1.29–1.58)*

HCV genotype

<0.001

1

1 (reference)

2

0.74 (0.62–0.89)*

3

1.27 (1.04–1.55)*

Other

0.99 (0.63–1.54)

History of alcohol abuse

<0.001

No

1 (reference)

Yes

2.32 (2.08–2.59)*

HIV coinfection

<0.001

No

1 (reference)

Yes

1.86 (1.45–2.39)*

Diabetes (Charlson/Deyo
comorbidity subscore)

<0.001

No

1 (reference)

Yes

1.39 (1.18–1.64)*

95% CI, 95% conﬁdence interval; HCV, hepatitis C virus.
*Adjusted odds ratio is statistically signiﬁcant at alpha = 0.05 level.

The American Journal of GASTROENTEROLOGY

Our finding that HCV infection acquired through blood transfusion
is associated with higher rates of cirrhosis is in agreement with
earlier retrospective studies that reported more aggressive histological inflammatory activity and a higher risk of hepatic
decompensation in patients with transfusion-acquired hepatitis
C (31,32). Our observation that duration of infection is a significant risk factor for the development of cirrhosis as assessed
by FIB-4 corroborates earlier reports that showed duration of
infection to be an independent predictor of advanced fibrosis in
hepatitis C-infected individuals (33,34). Our observation that the
duration of infection is positively associated with a higher likelihood of FIB-4-indicated cirrhosis also suggests that the FIB-4
test is a reliable predictor of cirrhosis. Finally, our observations
that infection with HCV genotype 3 increases the risk of cirrhosis
compared with infection with genotype 1, and that infection with
HCV genotype 2 is associated with a lower risk for cirrhosis, are
consistent with the recently-reported findings of Kanwal et al.
(35). That HCV viral genotype influences response to antiviral
therapy has been long recognized, but the finding that genotype
actually affects liver disease progression is a recent finding that
has significant implications regarding the modeling of this viral
epidemic.
Our study has significant strengths, including the large size
and diversity of the cohort (22,36). The cohort is drawn from
four large integrated health systems that serve almost 4 million
individuals in five geographically and racially distinct states. This
study is unique because it used an expanded set of parameters
(liver biopsy, the serum fibrosis marker FIB-4, and the presence
of diagnostic/procedure codes for cirrhosis and manifestations
of hepatic decompensation) to identify CHC patients with cirrhosis. The FIB-4 index employed in our study has been extensively validated in this large cohort for its ability to predict the
lower and upper ends of the liver fibrosis spectrum (F0–F2 and
cirrhosis, respectively) in both patients with hepatitis B virus
infection and HCV infection (23). The FIB-4 cutoff value of 5.88
that we used to identify cirrhosis in this study is conservative.
In the original validation study of FIB-4 in this cohort, a value
of 1.81 differentiated fibrosis stages 3–4 from fibrosis stages 0–2.
Accordingly, use of this lower cutoff would have identified an even
higher proportion of CHC patients with advanced fibrosis, some
with cirrhosis but with FIB-4 between 1.81 and 5.88. It must be
emphasized, however, that this study reports period prevalence of
cirrhosis between 2006 and 2010, and not the prevalence at a single
point in time.
Our study has inherent limitations. The FIB-4 index is based
on laboratory values (alanine and aspartate aminotransferase
values and platelet counts) that may fluctuate over time, and
such natural fluctuations may occur during the course of HCV
infection. However, we used the most recently available aminotransferase levels and platelet counts collected within 7 days
of each other, rather than peak values, reducing the likelihood
that we captured spurious elevations. Furthermore, we excluded
laboratory values collected while a patient was receiving antiviral therapy in order to eliminate any influence of therapy on
these laboratory values. Our sensitivity analysis also excluded
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laboratory values collected from hospitalized patients who may
have had spurious platelet count or aminotransferase values during hospitalization for reasons unrelated to their liver disease.
Although the FIB-4 score has been shown to have an area under
the receiver operating characteristic curve value of 85% in predicting cirrhosis in our cohort (23), it is not diagnostic and does
not identify cirrhosis in patients with low or normal transaminase levels and those who have normal platelet counts. Although
we would have liked to combine this noninvasive test score with
an assessment of liver stiffness to improve the test performance,
the observational nature of our study precluded the collection
of liver stiffness data. Moreover, liver stiffness tests had not
been approved at the time of conduct of our study. Finally, the
CHeCS cohort represents patients known to health systems and
diagnosed with CHC; thus, our estimate of cirrhosis prevalence
cannot be extrapolated to the undiagnosed HCV-infected population or to infected patients who have not had encounters with
the health-care system.
Retrospective studies evaluating the economic impact of CHC,
and Markov models evaluating the cost effectiveness of newer
anti-HCV therapies, have typically relied on ICD-9 codes to
identify and stratify patients on the basis of disease severity
(17,37–40). Our finding that only one-half of all patients with
biopsy-confirmed cirrhosis have ICD-9 codes assigned to them
suggests that estimates of the economic burden reported by these
retrospective studies and Markov models may be very conservative. Moreover, these cost-effectiveness models are based on
baseline estimates of the prevalence of cirrhosis. If the actual
prevalence is higher than the current estimates, as is suggested
by the results of our study, these models will need to be revised
accordingly, which may result in significantly different findings with regard to the cost-effectiveness of the newer antiviral
therapy regimens.
In conclusion, our study suggests that the prevalence of cirrhosis in CHC patients is higher than would be diagnosed through
the use of liver biopsies and ICD-9 codes alone. Prospective studies of the natural history of CHC have reported the development
of cirrhosis in 7–16% of patients over 8–16 years of follow-up
(41–44), whereas retrospective–prospective studies with exposure
intervals of 9–45 years have reported progression to cirrhosis in
0.3–15% of CHC patients (45–51). Our study also reveals that
less than one-half of all CHC patients (43% in our cohort) underwent liver biopsy, and that use of additional parameters including FIB-4 scores and ICD-9/CPT codes for cirrhosis and hepatic
decompensation likely facilitated a more accurate estimate of the
prevalence of cirrhosis in a CHC population. Accurate estimation of the prevalence of advanced fibrosis or cirrhosis has significant implications for patient care and health-care policy. There
has been recent interest in the use of noninvasive modalities
including elastography and blood tests for the diagnosis of liver
fibrosis in patients with hepatitis C, and the use of these noninvasive modalities in lieu of liver biopsy has been widely discussed
(52,53). Our findings suggest that the use of FIB-4 and APRI
scores facilitates more accurate estimation of the prevalence of
cirrhosis in CHC patients than would be possible through the use
© 2015 by the American College of Gastroenterology

of biopsy alone. Serum markers such as FIB-4 and APRI scores,
which are easily calculable with online tools that use readily available demographic and laboratory parameters (54), could prove
clinically useful if included as part of the comprehensive clinical profile of CHC patients. Cirrhosis has likely been underdiagnosed in the past because of patient reluctance to undergo liver
biopsy. Use of these noninvasive modalities will help address this
underdiagnosis and provide more reliable estimates of the true
prevalence of advanced fibrosis. Knowledge of the actual prevalence of advanced fibrosis will also help inform clinical decision
making regarding screening for sequelae of CHC, timing of initiation of antiviral therapy, and follow-up counseling. Our findings
are the first in the United States to attempt an accurate estimate
of the prevalence of cirrhosis in the CHC patient population at
large. These findings heighten awareness of the health-care burden imposed by advancing HCV disease progression in the US
population.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE

✓ The prevalence of chronic hepatitis C (CHC)-related cirrhosis is uncertain.
✓ Previous studies may underestimate the true prevalence of
cirrhosis in CHC patients.

WHAT IS NEW HERE

✓ Use of additional parameters to identify cirrhosis suggests
a fourfold higher prevalence compared with liver biopsy
alone.

✓ A signiﬁcant proportion of patients with biopsy-conﬁrmed
cirrhosis are not assigned International Classiﬁcation of
Diseases, Ninth Revision (ICD-9) codes for cirrhosis.
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